S-1/A: CERo Therapeutics Eyes \$20 Million Capital Injection Through Share and Warrant Offering

CERo Therapeutics aims to raise capital to advance its clinical programs and for general corporate purposes through a public offering of common stock, pre-funded warrants, and common warrants.

Summary

• CERo Therapeutics is planning a public offering to sell up to 4,000,000 shares of common stock, along with common warrants to purchase an equal number of shares.
• The offering also includes the option for certain purchasers to buy pre-funded warrants in lieu of common stock, up to 4,000,000 shares.
• Each share of common stock or pre-funded warrant will be sold with a common warrant to purchase one share of common stock.
• The assumed public offering price is \$2.00 per share, based on the closing price on February 3, 2025.
• The common warrants will be exercisable upon stockholder approval or if certain pricing conditions are met, with an exercise price to be determined.
• The offering is expected to terminate on February 15, 2025, but may be terminated earlier at the company's discretion.
• The company intends to use the net proceeds for clinical programs, working capital, and general corporate purposes, including potential redemption of preferred stock.
• A.G.P./Alliance Global Partners is acting as the exclusive placement agent for the offering, receiving a fee of 6% of the gross proceeds.
• The company's stock is listed on Nasdaq under the ticker symbol CERO.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has a promising technology and has cleared a regulatory hurdle, it also faces significant financial challenges and competition. The capital raise is necessary but also dilutive.

Positives

• The company has a lead drug candidate, CER-1236, with a novel mechanism of action.
• The FDA has cleared the IND for CER-1236, allowing the company to proceed with clinical trials.
• The company has engaged A.G.P./Alliance Global Partners as the exclusive placement agent for the offering.
• The company has a cash balance of approximately \$5.539 million as of January 7, 2025.
• The company has obtained an extension from Nasdaq to regain compliance with listing requirements.

Negatives

• The company has a history of net losses and expects to continue incurring losses.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company is dependent on the success of its lead product candidate, CER-1236.
• The company's engineered CER-T cells represent a novel approach to cancer treatment that creates significant challenges.
• The company faces competition from companies that have developed or may develop product candidates for the treatment of the diseases that it may target.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its securities.
• The company's Public Warrants will become exercisable for its common stock, which would increase the number of shares eligible for future resale in the public market and would result in dilution to its stockholders.

Risks

• The shares of Common Stock being offered in this prospectus represent a substantial percentage of the outstanding shares of Common Stock, and the sales of such shares, or the perception that these sales could occur, could cause the market price of the Common Stock to decline significantly.
• Sales of a substantial number of our securities in the public market by our existing securityholders could cause the price of our Common Stock and Warrants to fall.
• Certain existing securityholders purchased our securities at a price below the current trading price of such securities, and may experience a positive rate of return based on the current trading price. Future investors in us may not experience a similar rate of return.
• We have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability. Our independent registered public accountants have expressed substantial doubt as to our ability to continue as a going concern.
• Our business is highly dependent on the success of our lead product candidate. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidate for the treatment of patients in approved indications, our business would be significantly harmed.
• Our engineered CER-T cells represent a novel approach to cancer treatment that creates significant challenges for us.
• Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or to commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.
• Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials.
• Manufacturing genetically engineered products is complex and we, or our third-party manufacturers, may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.
• If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidate for the treatment of patients in approved indications, our business would be significantly harmed.
• Genetic engineering of T cells to create CER-T cells is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.
• We will depend on enrollment of patients in our clinical trials for our product candidates. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• We face competition from companies that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel therapies and platform technologies. If these companies develop platform technologies or product candidates more rapidly than we do, if their platform technologies or product candidates are more effective or have fewer side effects, our ability to develop and successfully commercialize product candidates may be adversely affected.
• We operate in a rapidly changing industry and face significant competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
• We are highly dependent on our key personnel, including individuals with expertise in cell therapy development and manufacturing, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
• We will need substantial additional financing to develop our products and implement our operating plans, which financing we may be unable to obtain, or unable to obtain on acceptable terms. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.
• We maintain single supply relationships for certain key components, and our business and operating results could be harmed if supply is restricted or ends or the price of raw materials used in our suppliers manufacturing process increases.
• Regulatory requirements in the United States and abroad governing cell therapy products have changed frequently and may continue to change in the future, which could negatively impact our ability to complete clinical trials and commercialize our product candidates in a timely manner, if at all.
• Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products, services and brand.
• An active trading market for our Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. The price of our Common Stock may be extremely volatile, and stockholders could lose all or part of their investment.
• Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities.
• Since the completion of our Initial Public Offering, there has been a precipitous drop in the market values of companies formed through mergers involving special purpose acquisition companies. Accordingly, securities of companies such as ours may be more volatile than other securities and may involve special risks.
• Securities of companies formed through mergers with special purpose acquisition companies such as ours may experience a material decline in price relative to the share price of the special purpose acquisition companies prior to the merger.
• Our Public Warrants will become exercisable for our common stock, which would increase the number of shares eligible for future resale in the public market and would result in dilution to our stockholders.
• The issuance of shares of our Common Stock upon conversion or exercise of our outstanding Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C Warrants and other securities that we may issue in future financing transactions may result in substantial dilution to our stockholders.
• There is no public market for Offered Common Warrants or the Pre-Funded Warrants to purchase shares of our common stock being offered by us in this offering.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it continues its R&D activities, pursues preclinical studies and initiates clinical trials, seeks regulatory approvals, establishes sales, marketing and distribution infrastructure, and develops its manufacturing process.

Industry Context

The announcement relates to the broader industry trend of developing novel immunotherapies for cancer treatment, particularly engineered T cell therapies. The company is positioning its CER-T cell therapy as a next-generation approach that can overcome the limitations of existing CAR-T cell therapies, especially in solid tumors.

Comparison to Industry Standards

• The document mentions approved CAR-T therapies like Yescarta, Kymriah, and Breyanzi, which are primarily effective in hematological B cell malignancies.
• CERo Therapeutics is positioning CER-1236 as a potential treatment for both hematological malignancies and solid tumors, unlike the current CAR-T therapies.
• The document highlights the limitations of current CAR-T therapies in solid tumors, such as difficulty in targeting tumor-associated antigens and the immunosuppressive tumor microenvironment.
• The document mentions competing companies developing TCR T therapies, CAR-NK, TIL and T cell engager technologies, including Gilead Sciences, Bristol-Myers Squibb, Amgen, Nkarta Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., and Fate Therapeutics Inc.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the offering and the exercise of warrants.
• Employees will be impacted by the company's ability to continue funding R&D and operations.
• Patients may benefit from the development of new cancer therapies.

Next Steps

• Advance clinical development of CER-1236 for the treatment of AML patients.
• Expand CER-1236 development activities to target solid tumors.
• Continue to seek additional financing to support operations and R&D activities.

Key Dates

Keywords

public offering, common stock, warrants, CER-T, CERo Therapeutics, capital raise, clinical trials, biotechnology, immunotherapy, financing